The FDA approved Imfinzi (durvalumab) plus Padcev (enfortumab vedotin-ejfv) before bladder removal, then Imfinzi alone afterward, for adults with muscle-invasive bladder cancer who cannot receive or decline cisplatin-based chemotherapy. In Rezolute’s preliminary single-arm Phase 3 upLIFT readout of ersodetug for tumor-related hyperinsulinism, 13 of 16 patients at least halved their IV glucose infusion rate, including 12 who stopped IV glucose. The November 12–13 roundup covers split European recommendations on Baxfendy (baxdrostat) and Meplyffa (arimoclomol), plus Intellia’s hereditary angioedema data. Windward Bio priced its IPO alongside a planned Sanofi placement, and Bristol Myers Squibb is unifying R&D.Alex Mercer and Maya Patel host. Get the daily rundown in your inbox — subscribe at https://thepharmacloseout.com.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →